Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
DAVID MARCUS: Trump’s base trusts him to play...
Trump weighs striking Iranian nuclear facilities: ‘I may...
GOP says Dems admit ‘guilt’ in Biden health...
Poll position: Where Trump stands in the eyes...
Ilhan Omar claims no one has ‘attacked Americans,’...
‘Squad’ members, GOP lawmaker join forces to reject...
Vance defends Gabbard as ‘critical part’ of Trump...
Trump downplays signs of MAGA unrest over possible...
‘Instincts for restraint’: Senate divided over who gets...
Top Trump ally predicts Senate will blow past...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Sona Nanotech’s Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference

by admin February 12, 2025
February 12, 2025
Sona Nanotech’s Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the ‘Company’, ‘Sona’) is pleased to announce that its recently published findings from its ‘Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors’ study will be presented at the international 19th Canadian Melanoma Conference on February 20th in Vancouver. Sona’s Chief Medical Officer, Dr. Carman Giacomantonio, a planning committee member for this conference, and Dr. Barry Kennedy, of The Giacomantonio Immuno-Oncology Research Group, will present both poster and oral presentations.

The conference is presented by OncologyEducation and is Canada’s flagship meeting on the research and treatment of melanoma, bringing together medical oncologists, surgeons, dermatologists, radiotherapists, pathologists, immunologists, molecular biologists and industry partners to review the latest research and explore new therapies.

Contact:
David Regan, CEO
+1-902-442-0653
david@sonanano.com

About Sona Nanotech Inc.
Sona Nanotech is developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona’s gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech’s gold nanorod particles are cetyltrimethylammonium (‘CTAB’) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain ‘forward-looking statements’ under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, and Sona’s preclinical and clinical study plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Not for distribution to United States newswire services or for dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240541

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

previous post
Heliostar Metals: Gold Miner with a Portfolio of Producing, Developing Gold Projects in Mexico
next post
CHARBONE Hydrogen Announces New Board Director and Other Corporate Updates

You may also like

Term Sheet for Hydrogen Supply and Offtake with...

January 6, 2025

First Helium Secures Rig to Drill Two Wells...

January 15, 2025

Cobalt Price Recovery Uncertain as Battery Chemistry Shifts...

November 16, 2024

Red Metal Resources Plans Extensive 2025 Work Program...

February 27, 2025

Crypto Market Recap: Australia to Start Crypto Pilot...

March 24, 2025

Syntheia Announces First 1,000 Subscriptions

February 15, 2025

Kaiser to acquire the Henty Gold Mine, becoming...

March 24, 2025

As Part of Its New Development Strategy, Cartier...

February 15, 2025

Top 5 Canadian Mining Stocks This Week: Euro...

April 5, 2025

Strong Search and Cloud Revenues Propel Alphabet Past...

July 25, 2024

Recent Posts

  • DAVID MARCUS: Trump’s base trusts him to play strong hand in Iran
  • Trump weighs striking Iranian nuclear facilities: ‘I may do it, I may not do it’
  • GOP says Dems admit ‘guilt’ in Biden health cover-up by boycotting Senate hearing on ‘constitutional scandal’
  • Poll position: Where Trump stands in the eyes of Americans five months into his second presidency
  • Ilhan Omar claims no one has ‘attacked Americans,’ but Iran’s deadly history tells different story

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (792)
    • Investing (2,350)
    • Politics (2,910)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.